Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz

Logo MUG-Forschungsportal

Gewählte Publikation:

Ploner, F; Jakesz, R; Hausmaninger, H; Kolb, R; Stierer, M; Fridrik, M; Steindorfer, P; Gnant, M; Haider, K; Mlineritsch, B; Tschurtschenthaler, G; Steger, G; Seifert, M; Kubista, E; Samonigg, H; Austrian Breast And Colorectal Cancer Study Group.
Randomised trial: One cycle of anthracycline-containing adjuvant chemotherapy compared with six cycles of CMF treatment in node-positive, hormone receptor-negative breast cancer patients.
Onkologie. 2003; 26(2):115-119 Doi: 10.1159/000069831
Web of Science PubMed FullText FullText_MUG Google Scholar


Führende Autor*innen der Med Uni Graz
Ploner Ferdinand
Co-Autor*innen der Med Uni Graz
Hofmann Guenter
Samonigg Hellmut

Dimensions Citations:

Plum Analytics:

Scite (citation analytics):

AIM: A randomised, controlled clinical trial was initiated in 1984 to test whether 1 cycle of anthracycline-containing adjuvant chemotherapy improves the outcome of breast cancer patients presenting with stage II disease and negative oestrogen and progesterone receptors (ER, PgR), as compared with 6 cycles of dose-reduced CMF. PATIENTS AND METHODS: Within 7 years 263 women with stage II breast cancer were randomised either to receive 1 cycle of doxorubicin, vinblastine, cyclophosphamide, methotrexate and 5- fluorouracil (AV-CMF) or to receive 6 cycles of cyclophosphamide, methotrexate and 5-fluorouracil (CMF). Patients were stratified for tumour stage, nodal stage, menopausal status, type of surgery and participating centre. RESULTS: After a median follow-up of 100 months, neither disease-free (DFS) nor overall survival (OS) differed significantly between the two groups. CONCLUSIONS: Compared to 6 cycles of a non-standard low-dose CMF regimen 1 cycle of anthracycline- containing adjuvant chemotherapy failed to improve the outcome in women with stage II receptor-negative breast cancer in terms of DFS and OS.
Find related publications in this database (using NLM MeSH Indexing)
Antineoplastic Combined Chemotherapy Protocols - adverse effects
Breast Neoplasms - drug therapy
Carcinoma, Ductal, Breast - drug therapy
Carcinoma, Lobular - drug therapy
Chemotherapy, Adjuvant - drug therapy
Cisplatin - adverse effects
Combined Modality Therapy - adverse effects
Cyclophosphamide - adverse effects
Disease-Free Survival - adverse effects
Dose-Response Relationship, Drug - adverse effects
Doxorubicin - adverse effects
Drug Administration Schedule - adverse effects
Female - adverse effects
Fluorouracil - adverse effects
Humans - adverse effects
Lymphatic Metastasis - adverse effects
Methotrexate - adverse effects
Middle Aged - adverse effects
Neoplasm Staging - adverse effects
Receptors, Estrogen - analysis
Receptors, Progesterone - analysis
Survival Rate - analysis
Vincristine - adverse effects

Find related publications in this database (Keywords)
breast cancer
adjuvant therapy
© Med Uni Graz Impressum